Scientists have uncovered genetic variants that help clarify why weight-loss drugs such as Wegovy and Mounjaro work considerably better for some people than others, according to findings from the journal Nature. A examination involving 15,000 people taking these medications found that those carrying specific gene variations shed considerably more weight over roughly eight months of treatment. Whilst participants lost an average of 11.7 per cent of their body weight, some shed as much as 30 per cent whilst others saw little change. The findings could also provide insight into why certain individuals suffer severe adverse effects including nausea and vomiting. Experts suggest the genetic factors, though relatively modest in effect, work alongside other elements such as age, sex and ethnic background to influence how well these common weight-management treatments perform.
The genetic breakthrough revolutionising obesity management
Researchers analysing data from 23andMe discovered two key genetic variants that substantially affect how well weight-loss medications work. The first variant, linked to appetite regulation and digestion, is associated with greater weight loss when taking drugs like Wegovy and Mounjaro. People carrying a single copy of this variant lose approximately 0.76 kilogrammes more on average, whilst those with two copies can double that additional weight loss. The variant is especially prevalent among people of European ancestry, with 64 per cent carrying one copy and 16 per cent carrying two, compared to just 7 per cent of African Americans.
The second gene variant discovered in the study is associated with severe gastrointestinal side-effects when using tirzepatide, the key component in Mounjaro. Researchers determined that roughly 1 per cent of people carrying this variant experience extremely intense vomiting—nearly 15 times worse than typical side-effects. Professor Ruth Loos from the University of Copenhagen, who commented on the research, stressed that whilst the genetic effects are fairly modest, they are comparable to other influential factors and should not be overlooked as insignificant in determining how individuals respond to drugs.
- Genetic variants affect weight loss by roughly 0.76 kilogrammes per person
- European ancestry populations show higher prevalence of weight-loss associated genes
- Second genetic variant increases risk of severe nausea and vomiting
- Genetic factors work alongside age, sex and ethnicity in determining effectiveness
How genetic factors influence medication effectiveness
The weight-loss version explained
The primary genetic variant discovered in the research influences the body’s appetite regulation and metabolic function, directly affecting how weight-loss medications function. Individuals carrying this variant experience improved weight loss when taking drugs such as Wegovy and Mounjaro, with studies showing an additional 0.76 kilogrammes reduced on average basis relative to those without the variant. The mechanism is related to how the genes work with the medications’ appetite-suppressing properties, enhancing their efficacy in suppressing hunger and increasing satisfaction across the treatment period.
The impact becomes even more marked for those possessing two copies of the genetic variant. These persons can effectively increase their additional weight loss, potentially achieving considerable gains over those with one copy when pursuing weight management therapy. This dual-copy genetic effect constitutes a meaningful distinction in results, particularly meaningful for patients looking for optimal treatment outcomes. However, scientists stress that this hereditary benefit comes with drawbacks, as carriers also experience increased GI side-effects, including nausea and vomiting in the course of treatment.
Ancestry and genetic distribution
The prevalence of this weight-loss associated genetic variant varies considerably across different populations, with ancestry serving as a key factor in likelihood of inheritance. European ancestry populations exhibit markedly greater carrier rates in comparison with other ethnic groups, highlighting genetic diversity across global populations. This disparity presents important considerations for personalised treatment strategies and understanding why weight-loss drug efficacy may vary among individuals from different ethnic backgrounds, thereby impacting treatment planning and outcome expectations.
| Population Group | Percentage Carrying Gene Variant |
|---|---|
| European ancestry (one copy) | 64% |
| European ancestry (two copies) | 16% |
| African American (one copy) | 7% |
| African American (two copies) | Data not specified |
Understanding these hereditary patterns helps explain observed variations in drug response across diverse groups. The notably elevated prevalence of the weight-loss variant among people of European descent suggests they may exhibit more pronounced advantages from these medications on average. Conversely, lower carrier rates in African American communities indicate different genetic profiles that may necessitate alternative treatment strategies or modified expectations regarding weight-loss outcomes with current obesity medications.
Beyond hereditary factors: the broader context
Whilst inherited differences offer valuable insights into how people respond to drugs, researchers emphasise that inherited factors constitute only one piece of a much bigger puzzle. Professor Ruth Loos observes that the hereditary influence, though limited, remains “similar to other factors – and not trivial.” This means that numerous additional variables affect how effectively weight-loss medications work for each person. Sex, age, daily habits, metabolic rate and overall health status all contribute meaningfully to results from treatment, sometimes outweighing hereditary tendency entirely.
The intricacy of personalised medicine is highlighted when examining how 15,000 trial participants experienced widely varying weight loss despite receiving identical pharmaceutical treatments. Some shed 30 per cent of their body weight across eight months, whilst others experienced minimal loss. This pronounced inconsistency underscores that heredity in isolation is unable to forecast success. Environmental factors, compliance with treatment regimens, eating patterns and unique biological makeup work together with genetic code to establish end results, pointing to the need for a sophisticated strategy to weight management is essential.
- Sex differences may influence drug metabolism and weight reduction results substantially
- Age shapes metabolic processes and drug efficacy in observable fashion
- Ethnic background shapes both genetics and environmental health influences
- Lifestyle choices and dietary habits remain crucial despite genetic factors
- Individual health conditions influence medication responses in unpredictable ways
Sex, age and ethnic considerations
Sex differences have a significant impact in shaping how weight-loss medications affect individuals, with emerging evidence suggesting men and women might have varying responses to drugs like Wegovy and Mounjaro. Hormonal variations, differences in body composition and distinct metabolic patterns between sexes may affect drug bioavailability and performance. Age similarly impacts treatment success, as older people generally experience slower metabolic rates and might encounter different medication breakdown compared to younger people, which may influence weight loss patterns and side-effect intensity.
Ethnicity covers both genetic and socioeconomic dimensions that affect medication outcomes beyond straightforward hereditary factors. Dietary customs across cultures, healthcare access, the affordability of medications and lifestyle factors show substantial variation across ethnic groups, all impacting how well weight-loss medications work. Researchers acknowledge that understanding these intersecting variables demands thorough examination beyond genetic analysis alone, ensuring that future treatment guidelines cater to diverse populations fairly and effectively.
From laboratory findings to clinical application
The discovery of genetic variations affecting weight-management medication effectiveness creates exciting opportunities for personalised medicine in obesity treatment. Translating these research results into clinical practice demands careful consideration of how genetic testing could be integrated into NHS prescribing protocols and private medical services. Healthcare professionals may eventually use genetic testing to predict which patients will show the best response to specific medications, potentially improving treatment outcomes and minimising unnecessary side-effects. However, introducing such screening at scale presents logistical and financial obstacles that the health service must address systematically.
Current obesity treatment remains largely one-size-fits-all, with patients being prescribed identical medications irrespective of their genetic makeup. As genetic understanding advances, clinicians could tailor prescriptions to individual genetic profiles, maximising weight loss whilst minimising adverse reactions. This shift towards precision medicine demands investment in genetic testing infrastructure, healthcare worker training and updated clinical guidelines. The research suggests that whilst genetic factors play a modest role, their identification alongside monitoring of other variables could substantially improve treatment efficacy and patient satisfaction across diverse populations.
The precision medicine opportunity
Precision medicine constitutes a key transformation from uniform therapeutic approaches towards individualised healthcare strategies based on genetic and phenotypic characteristics. By identifying which patients carry favourable genetic differences, clinicians could enhance pharmaceutical selection and dosing regimens, thereby enhancing weight loss outcomes whilst reducing nausea and vomiting complications. This approach offers better resource allocation, improved patient experiences and greater assurance in weight management across the NHS and private sector.
- Genetic screening could predict how individual patients respond to drugs reliably
- Personalised dosing regimens may minimise harmful side effects considerably
- Precision approaches improve patient satisfaction with treatment and therapeutic results substantially
What that means for patients today
For the vast numbers of people currently taking weight-loss medications like Wegovy and Mounjaro, these genetic discoveries offer valuable understanding into why their experiences differ so dramatically. Whilst hereditary elements represent only a limited effect on treatment success, they work alongside other major factors including sex, age and racial heritage to shape specific responses. Understanding these variations helps account for why some patients experience significant weight losses of 30 per cent or more, whilst others see scant improvement despite taking equivalent treatments. This knowledge validates the frustration many patients experience when treatments do not produce expected benefits, suggesting physiological elements rather than individual shortcoming play a significant role.
At present, the NHS and private clinics prescribe weight-loss drugs without genetic testing, which means patients are given standardised treatment irrespective of their individual genetic profile. The majority of individuals taking these drugs are often unaware whether they have genetic variants that could predict their reaction or vulnerability to side-effects such as severe nausea. Whilst genetic screening is not yet routinely available through the health service, this research provides a basis for future bespoke treatment methods. Patients discussing treatment options with medical professionals can now recognise that their genetic makeup may influence outcomes, potentially encouraging more informed conversations about practical expectations and personal risk considerations before beginning medication.